Soluble HLA in saliva of patients with autoimmune rheumatic diseases

被引:9
|
作者
Adamashvili, I
Pressly, T
Gebel, H
Milford, E
Wolf, R
Mancini, M
Sittg, K
Ghali, GE
Hall, V
McDonald, JC
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Surg, Shreveport, LA 71130 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Ctr Excellence Arthritis & Rheumatol, Shreveport, LA 71130 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Renal Transplantat & Tissue Typing Lab, Cambridge, MA 02138 USA
关键词
major histocompatibility complex; enzyme-linked immunosorbent assay; autoimmune rheumatic diseases;
D O I
10.1007/s00296-002-0173-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The limited number of studies addressing the presence of soluble human leukocyte antigen (HLA) in body fluids such as tears, urine, sweat, and saliva are restricted to healthy subjects. In this study, we applied solid-phase enzyme-linked immunoassay to quantify soluble HLA class I (sHLA-I) and class II (sHLA-II) molecules in saliva and in selected serum samples obtained from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren's syndrome (SS). Results: While saliva from normal subjects (n = 35) contained levels of sHLA-I that were undetectable (n = 7) or ranged from 9 ng/ml to 70 ng/ml (30 +/- 3.7 ng/ml, n = 28), sHLA-I among 38 patients with moderately active RA (n = 24) or SLE (n = 14) were significantly elevated (222 +/- 81.4 ng/ml and 120 +/- 27.3 ng/ml, respectively, P<0.0001). Intriguingly, sHLA-I levels were even higher in patients whose disease was regarded as active. Specifically, sHLA-I averaged 683 1189 ng/ml in patients with active RA (n = 13) and 230 +/- 24.5 ng/ml in patients with active SLE (n = 7). This was significantly higher than in patients with milder forms of these diseases (P<0.0001). All five subjects with SS had severe disease with high levels of sHLA-I (mean 486 +/- 86 ng/ml). The concentrations of saliva sHLA-II in the disease groups studied were comparable with levels found in normal controls. The sHLA-I in severe and mild states was investigated in purified serum and saliva from a patient with SS. While 44-kDa fragments of serum HLA-I were detectable in severe SS, they were undetectable in saliva HLA at any time; 35-37-kDa fragments of serum or saliva HLA-I were detected during both mild and severe disease. Interestingly, the 39-kDa fragment was detected in both body fluids during severe but not mild forms of SS. Similarly, the isoforms with the molecular masses 39 kDa and 44 kDa were mainly identified in the purified material obtained from serum of SLE patients. Conclusions: Collectively, our data suggest that the measurement of soluble HLA in body fluids can be of both diagnostic and prognostic value in the assessment of patients with autoimmune rheumatic disorders. The mechanism by which sHLA enters saliva is unclear, but they probably are not acquired from serum.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [21] Frequency of rheumatic diseases in patients with autoimmune thyroid disease
    Soy, Mehmet
    Guldiken, Sibel
    Arikan, Ender
    Altun, Betul Ugur
    Tugrul, Armagan
    [J]. RHEUMATOLOGY INTERNATIONAL, 2007, 27 (06) : 575 - 577
  • [22] Rheumatic Disease Autoantibodies in Patients with Autoimmune Thyroid Diseases
    Nisihara, Renato
    Pigosso, Yasmine Gorczevski
    Prado, Nathalia
    Utiyama, Shirley R. R.
    De Carvalho, Gisah A.
    Skare, Thelma L.
    [J]. MEDICAL PRINCIPLES AND PRACTICE, 2018, 27 (04) : 332 - 336
  • [23] Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases
    Gupta, Vikas
    Gupta, Vikram Kumar
    Bajwa, Navjot Kaur
    Sachdeva, Ashi
    Garg, Rupali
    Ghosh, Abhra
    [J]. JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (05) : 1904 - 1910
  • [24] Frequency of rheumatic diseases in patients with autoimmune thyroid disease
    Mehmet Soy
    Sibel Guldiken
    Ender Arikan
    Betul Ugur Altun
    Armagan Tugrul
    [J]. Rheumatology International, 2007, 27 : 575 - 577
  • [25] SOLUBLE CD8 IN PATIENTS WITH RHEUMATIC DISEASES
    SYMONS, JA
    WOOD, NC
    DIGIOVINE, FS
    DUFF, GW
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1990, 80 (03): : 354 - 359
  • [26] Neopterin in autoimmune rheumatic diseases
    Nassonov, EL
    Samsonov, MY
    Wirleitner, B
    Tilz, GP
    Fuchs, D
    [J]. PTERIDINES, 1999, 10 (03) : 119 - 124
  • [27] AUTOIMMUNE REACTIONS IN RHEUMATIC DISEASES
    MAERKERALZER, G
    [J]. INTERNIST, 1990, 31 (01): : 19 - 25
  • [28] AUTOIMMUNE RHEUMATIC DISEASES AND OSTEOPOROSIS
    Athanassiou, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S102 - S102
  • [29] Autoimmune rheumatic diseases and cancer
    Casciola-Rosen, Livia
    Shah, Ami
    Rosen, Antony
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [30] Biomarkers in autoimmune rheumatic diseases
    Wilson, Hannah
    [J]. BIOMARKERS IN MEDICINE, 2015, 9 (06) : 497 - 498